Different changes in cortical tumor necrosis factor-α-related pathways in schizophrenia and mood disorders

Molecular Psychiatry

Volumn 18, Issue 7, 2013, Pages 767-773

  Dean, B ^a   Gibbons, A S ^a   Tawadros, N ^a   Brooks, L ^a   Everall, I P ^a   Scarr, E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

bipolar disorder; cortex; major depressive disorders; schizophrenia; tumor necrosis factor

Indexed keywords

INTERLEUKIN 18; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ARTICLE; ASTROCYTE; BIPOLAR DISORDER; BRODMANN AREA 24; BRODMANN AREA 46; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MAJOR DEPRESSION; MICROGLIA; NERVE CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BIPOLAR DISORDER; CASE-CONTROL STUDIES; CEREBRAL CORTEX; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879410148     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.95     Document Type: Article

References (69)

1. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol 2011; 14: 997-1012.
2. O'Brien SM, Scully P, Dinan TG. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatr Res 2008; 160: 256-262.
3. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009; 59: 123-129.
4. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001; 11: 203-208.
5. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychophamacol (Berlin) 2003; 170: 429-433.
6. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG. Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med 2006; 36: 37-43.
7. Yang K, Xie G, Zhang Z, Wang C, Li W, Zhou W et al. Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression. Aust N Z J Psychiatr 2007; 41: 266-273.
8. Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuro-psychopharmacol Biol Psychiatr 2007; E31: 1044-1053.
9. Pavon L, Sandoval-Lopez G, Eugenia HM, Loria F, Estrada I, Perez M et al. Th2 cytokine response in major depressive disorder patients before treatment. J Neuroimmunol 2006; 172: 156-165.
10. Penninx BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatr 2003; 54: 566-572.
11. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Dis 2006; 90: 263-267.
12. Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatr 2009; 65: 481-488.
13. Ortiz-Dominguez A, Hernandez ME, Berlanga C, Gutierrez-Mora D, Moreno J, Heinze G et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 2007; 9: 596-602.
14. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early-vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 447-458.
15. Na KS, Kim YK. Monocytic, Th1 and th2 cytokine alterations in the pathophysiol-ogy of schizophrenia. Neuropsychobiology 2007; 56: 55-63.
16. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22: 370-379.
17. Huang TL, Lee CT. T-helper 1/T-helper 2 cytokine imbalance and clinical phenotypes of acute-phase major depression. Psychiatry Clin Neurosci 2007; 61: 415-420.
18. Monteleone P, Fabrazzo M, Tortorella A, Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 1997; 71: 11-17.
19. Liu L, Jia F, Yuan G, Chen Z, Yao J, Li H et al. Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis. Psychiatry Res 2010; 176: 1-7.
20. Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 2001; 47: 13-25.
21. Suvisaari J, Loo BM, Saarni SE, Haukka J, Perala J, Saarni SI et al. Inflammation in psychotic disorders: a population-based study. Psychiatr Res 2011; 189: 305-311.
22. Dean B, Tawadros N, Scarr E, Gibbons AS. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J Affect Dis 2010; 120: 245-248.
23. Pantelis C, Harvey CA, Plant G, Fossey E, Maruff P, Stuart GW et al. Relationship of behavioural and symptomatic syndromes in schizophrenia to spatial working memory and attentional set-shifting ability. Psychol Med 2004; 34: 693-703.
24. Critchley HD. Neural mechanisms of autonomic, affective, and cognitive integration. J Comp Neurol 2005; 493: 154-166.
25. Rogers MA, Kasai K, Koji M, Fukuda R, Iwanami A, Nakagome K et al. Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res 2004; 50: 1-11.
26. McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008; 5: 45-4.
27. Yan D, Qin N, Zhang H, Liu T, Yu M, Jiang X et al. Expression of TNF-alpha leader sequence renders MCF-7 tumor cells resistant to the cytotoxicity of soluble TNF-alpha. Breast Cancer Res Treat 2009; 116: 91-102.
28. Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004; 15: 353-366.
29. Esposito E, Cuzzocrea S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem 2009; 16: 3152-3167.
30. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
31. Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007; 157: 1275-1277.
32. Insel TR. Disruptive insights in psychiatry: transforming a clinical discipline. J Clin Invest 2009; 119: 700-705.
33. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10: 221-237.
34. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004; 173: 3916-3924.
35. Eastwood SL, Burnet PW, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 1995; 66: 309-319.
36. Craven SE, El-Husseini AE, Bredt DS. Synaptic targeting of the postsynaptic density protein PSD-95 mediated by lipid and protein motifs. Neuron 1999; 22: 497-509.
37. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatr 2000; 48: 766-777.
38. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroin-flammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010; 15: 384-392.
39. Ramilo O, Saez-Llorens X, Mertsola J, Jafari H, Olsen KD, Hansen EJ et al. Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation. J Exp Med 1990; 172: 497-507.
40. Ferrer I, Santpere G, Arzberger T, Bell J, Blanco R, Boluda S et al. Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe Study. J Neuropathol Exp Neurol 2007; 66: 35-46.
41. Dean B, Pavey G, Chai SY, Mendelsohn FAO. The localisation and quantification of molecular changes in the human brain using in situ radioligand binding and autoradiography. In: Dean B, Kleinman JE, Hyde TM (eds). Using CNS Tissue in Psychiatric Research: A Practical Guide. Harwood Academic Press: Amsterdam, 1999, pp 67-83.
42. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, Bray L, Eve DJ et al. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res 1995; 28: 311-318.
43. Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ et al. Human postmortem tissue: what quality markers matter? Brain Res 2006; 1123: 1-11.
44. Hill C, Keks N, Roberts S, Opeskin K, Dean B, Mackinnon A et al. Problem of diagnosis in postmortem brain studies of schizophrenia. Am J Psychiatry 1996; 153: 533-537.
45. Roberts SB, Hill CA, Dean B, Keks NA, Opeskin K, Copolov DL. Confirmation of the diagnosis of schizophrenia after death using DSM-IV: a Victorian experience. Aust N Z J Psychiatry 1998; 32: 73-76.
46. Foster P. Neuroleptic equivalence. Pharmaceut J 1989; 243: 431-432.
47. Dean B, Gray L, Scarr E. Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia. Aust N Z J Psychiatry 2006; 40: 217-224.
48. Scarr E, Gray L, Keriakous D, Robinson PJ, Dean B. Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder. Bipolar Disord 2006; 8: 133-143.
49. Dean B, Keriakous D, Scarr E, Thomas EA. Gene expression profiling in Brodmann's area 46 from subjects with schizophrenia. Aust N Z J Psychiatry 2007; 41: 308-320.
50. Udawela M, Scarr E, Hannan AJ, Thomas EA, Dean B. Phospholipase C beta 1 expression in the dorsolateral prefrontal cortex from patients with schizophrenia at different stages of illness. Aust N Z J Psychiatry 2011; 45: 140-147.
51. Lipska BK, ep-Soboslay A, Weickert CS, Hyde TM, Martin CE, Herman MM et al. Critical factors in gene expression in postmortem human brain: focus on studies in schizophrenia. Biol Psychiatry 2006; 60: 650-658.
52. Vandesompele J, De PK, Pattyn F, Poppe B, Van RN, De PA et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
53. D'Agostino RB, Belanger A, D'Agostino RB. A suggestion for using powerful and informative tests of normality. Am Statistician 1990; 44: 316-321.
54. Grubbs F. Procedures for detecting outlying observations in samples. Techno-metrics 1969; 11: 1-21.
55. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974.
56. Streiner DL, Norman GR. Health Measurement Scales: a Practical Guide to their Development and Use. Oxford University Press: New York, 2008.
57. Hailey KL, Li S, Andersen MD, Roy M, Woods Jr VL, Jennings PA. Pro-interleukin (IL)-1beta shares a core region of stability as compared with mature IL-1beta while maintaining a distinctly different configurational landscape: a comparative hydrogen/deuterium exchange mass spectrometry study. J Biol Chem 2009; 284: 26137-26148.
58. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012; 119: 651-665.
59. Wang Q, Charych EI, Pulito VL, Lee JB, Graziane NM, Crozier RA et al. The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and function. Mol Psychiatry 2011; 16: 1006-1023.
60. Millar JK, Christie S, Semple CA, Porteous DJ. Chromosomal location and genomic structure of the human translin-associated factor X gene (TRAX; TSNAX) revealed by intergenic splicing to DISC1, a gene disrupted by a translocation segregating with schizophrenia. Genomics 2000; 67: 69-77.
61. Canete JD, Llena J, Collado A, Sanmarti R, Gaya A, Gratacos J et al. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol 1997; 36: 38-42.
62. Roy A, Fung YK, Liu X, Pahan K. Up-regulation of microglial CD11b expression by nitric oxide. J Biol Chem 2006; 281: 14971-14980.
63. Lieberman AP, Pitha PM, Shin HS, Shin ML. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci USA 1989; 86: 6348-6352.
64. Morganti-Kossman MC, Lenzlinger PM, Hans V, Stahel P, Csuka E, Ammann E et al. Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol Psychiatry 1997; 2: 133-136.
65. Kirchner S, Holler E, Haffner S, Andreesen R, Eissner G. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 2004; 28: 67-74.
66. Kronhaus DM, Lawrence NS, Williams AM, Frangou S, Brammer MJ, Williams SC et al. Stroop performance in bipolar disorder: further evidence for abnormalities in the ventral prefrontal cortex. Bipolar Disord 2006; 8: 28-39.
67. Strakowski SM, Delbello MP, Adler CM. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry 2005; 10: 105-116.
68. Aloe L, Properzi F, Probert L, Akassoglou K, Kassiotis G, Micera A et al. Learning abilities, NGF and BDNF brain levels in two lines of TNF-alpha transgenic mice, one characterized by neurological disorders, the other phenotypically normal. Brain Res 1999; 840: 125-137.
69. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649-659.